The United Kingdom and the United States have secured a significant bilateral deal that will maintain zero levies on UK medicine shipments being sold in the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the NHS. This move secures that import taxes on these key exports will stay at zero for a timeframe of the next three years.
This deal is in response to previous warnings to dramatically increase tariffs on patented drug imports, with increases discussed up to 100%.
"This agreement with the United Kingdom reinforces the worldwide climate for new treatments and brings long-overdue equity to transatlantic drug exports," a release declared.
Economic Impact
Medicines constitute one of the UK's largest export categories to the America, which is by far the largest market for large UK drugmakers.
Statistics reveal that in the year leading up to September, the UK sold pharmaceutical products valued at billions to the US. This amount made up a significant portion of total UK exports in that period.
"This deal safeguards work, boosts investment and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a government official stated.
Specific NHS Changes
The deal includes several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to double total public funding on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments topped 20%.
Industry Background
This agreement takes place against a protracted tension between the drug companies and the UK government over spending levels and regulatory access.
These tensions were heightened by arguments that American consumers were paying a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had declined as a percentage of its resources over the past decade.
